Novo Nordisk Divests Ferrosan Shareholding

Diabetes care leader Novo Nordisk has completed a definitive agreement to sell its entire shareholding in Ferrosan to a holding company, making the Altor 2003 Fund the new majority shareholder in the Ferrosan group. The purchasing holding company is controlled by the Altor 2003 Fund and pre-existing shareholder Idosan.

Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_news.asp?guid=193996EF-4814-46F9-B764-37B33DB71320)